US FDA accepts resubmission of Amgen's Prolia
23 February 2010
Asher Mullard
Please Login to read the full article.
23 February 2010
Asher Mullard
asher.mullard@informa.com
The US FDA has accepted a resubmission of Amgen's bone drug Prolia (denosumab) for the treatment of postmenopausal osteoporosis (PMO) and set a PDUFA date of July 25th, 2010. After disappointing drug sales for Amgen in 2009, analysts are increasingly looking to the drug to provide the company with...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Iron chelator, prostate cancer conundrum on deck for ODAC
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
- With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
- Amgen fails to convince ODAC of Xgeva's benefit in prostate cancer
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
